---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-089330"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T23:35:10.337904+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Q2 net loss $5.7M; cash $24.6M; NXP900 IND cleared, Phase 1a expected Q3 2023

## Summary
- Cash $24.6M at June 30, 2023, up from $20.0M at Dec 31, 2022, enough into H1 2025.
- Net loss $5.7M vs $3.6M in Q2 2022; R&D expense $4.3M vs $2.5M.
- NXP800 Phase 1b in platinum-resistant ARID1a-mutated ovarian cancer ongoing; data expected Q1 2024.
- NXP900 IND cleared by FDA; Phase 1a dose escalation study set to begin in Q3 2023.
- Potential NXP800 expansion into cholangiocarcinoma supported by preclinical data.

## SEC filing metadata
- accession: 0001104659-23-089330
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465923089330/0001104659-23-089330-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465923089330/tm2323028d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-089330
- JSON: https://secwatch.observer/filing/0001104659-23-089330.json
- Plain text: https://secwatch.observer/filing/0001104659-23-089330.txt

## Key facts
- Earnings Releases
  Nuvectis Pharma, Inc. reported the second quarter ended June 30, 2023 results: net income $5.7 million.
  - Period: the second quarter ended June 30, 2023
  - Net income: $5.7 million
  - Result: reported results
  source text: Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465923089330/0001104659-23-089330-index.htm
- Earnings Releases
  Nuvectis Pharma, Inc. reported the second quarter ended June 30, 2023 results: net income $5.7 million.
  - Period: the second quarter ended June 30, 2023
  - Net income: $5.7 million
  - Result: reported results
  source text: The Company's net loss was $5.7 million for the three months ended June 30, 2023, compared to $3.6 million for the three months ended June 30, 2022, an increase of $2.1 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1875558/000110465923089330/0001104659-23-089330-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.